Restoring Skin Health

Oruka Therapeutics is advancing novel biologics that aim to redefine the standard of care for patients with chronic skin diseases. Oruka is both our name and our mission, derived from or, for “skin,” and arukah, for “restoration.”

Our proprietary portfolio targets the core mechanisms underlying plaque psoriasis, psoriatic arthritis, and other dermatologic and inflammatory indications. The investigational therapies we are developing are designed to offer patients suffering from chronic skin diseases the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year.

Our pipeline of potentially best-in-class antibodies was engineered by our partner, Paragon Therapeutics, which was founded by leading healthcare investor Fairmount. Oruka is the third company founded on discovery-stage assets from Paragon, following in the footsteps of Apogee Therapeutics (APGE) and Spyre Therapeutics (SYRE).